Related Experiment Video
Updated: Aug 26, 2026

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
Published on: June 2, 2015
Effects of oral anticoagulation with various INR levels in deep vein thrombosis cases
Ufuk Yetkin1, Ozalp Karabay, Hakan Onol
1Izmir Atatürk Education and Research Hospital, Department of Cardiovascular Surgery, TURKEY. ozalp.karabay@deu.edu.tr
Insights
Maintaining optimal anticoagulation is crucial for patients with venous thromboembolism. Higher International Normalized Ratio (INR) levels increase bleeding risks, with 2.0-2.5 proving sufficient for therapy.
Area of Science:
- Cardiovascular Surgery
- Hematology
- Pharmacology
Background:
- Thromboembolic disease necessitates long-term anticoagulant therapy.
- Monitoring anticoagulation levels, specifically the International Normalized Ratio (INR), is vital for patient safety.
- Bleeding complications are a significant concern in patients undergoing anticoagulant treatment.
Purpose of the Study:
- To compare bleeding complications in patients with venous thromboembolism based on achieved INR levels.
- To determine the optimal INR range for minimizing hemorrhage risk during long-term anticoagulation.
Main Methods:
- A study population of 364 patients with venous thromboembolism of the lower extremities was analyzed.
- Patients were divided into two groups based on INR: Group I (1.9-2.5) and Group II (2.6-3.5).
- Hemorrhage rates (minor and major) were assessed and compared between the two groups over a 6-month treatment period.
Main Results:
- Group II (INR 2.6-3.5) exhibited significantly higher minor hemorrhage rates (4.06%) compared to Group I (1.04%).
- Major hemorrhage rates were also substantially higher in Group II (6.3%) versus Group I (1.04%).
- INR values exceeding 2.5 were significantly associated with increased rates of both minor and major hemorrhage.
Conclusions:
- Close monitoring of oral anticoagulation is essential for patients with venous thromboembolism.
- Elevated INR levels (above 2.5) are linked to a significant rise in bleeding complications.
- An INR range of 2.0 to 2.5 is recommended for long-term anticoagulant therapy to balance efficacy and safety.
Abstract:
AIM: In order to avoid the complications associated with thromboembolic disease, patients with this condition typically are placed on long-term anticoagulant therapy. This report compares bleeding complications in this patient population by level of achieved INR. MATERIALS AND METHODS: During the 6-year period between January 1997 and January 2003, 386 patients with venous thromboembolism of the lower extremities were admitted to the Cardiovascular Surgery Outpatient Clinic of Alsancak State Hospital. Of the 386 patients, 198 (51.2%) were women, and the average age was 52.3 years. All diagnoses of venous thromboembolism were confirmed by means of Doppler ultrasonography. Further investigation showed occult neoplasms in 22 (5.6%) of the cases. We excluded the patients with occult disease, and the remaining 364 constituted our study population. RESULTS: Oral anticoagulation was standardized at 6 months' duration in all cases. We divided the patients into two groups. Group I consisted of 192 patients (52.7%) with INR values between 1.9 and 2.5; Group II comprised 172 patients with INR values between 2.6 and 3.5. Complications in each group were assessed and compared. The minor hemorrhage rate was 1.04% in Group I and 4.06% in Group II. The major hemorrhage rate was also 1.04% in Group I and was 6.3% in Group II. We determined that the complication rates for both minor and major hemorrhage were significant in patients with INR values above 2.5. CONCLUSION: Oral anticoagulation must be followed closely in patients with venous thromboembolism. Higher INR levels are associated with significant increases in hemorrhage and associated complications. INR values of 2.0 to 2.5 are sufficient for long-term anticoagulant therapy, ensuring ideal anticoagulation levels and minimizing the complication rate.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Venous Thrombosis IV: Nursing Management
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis I: Introduction